Close menu




October 25th, 2022 | 14:43 CEST

Core One Labs, XPhyto, BioNTech - The second biotech series moves forward

  • Biotechnology
Photo credits: pixabay.com

The enormously rapid development of the various COVID vaccines by historical standards showed how important biotechnology already is for humanity. Previously unknown companies such as BioNTech, Valneva and CureVac took center stage on the stock market and were able to multiply their share prices within a few months. Even after the pandemic, the biotech wheel continues to turn. Enormous growth opportunities are said to exist in the market for psychedelic drugs. Here, young growth companies are waiting in the wings with the potential to multiply their share prices in the future.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , CORE ONE LABS INC. | CA21872J2083

Table of contents:


    Infinite growth market

    While the growth curve for vaccine manufacturers against COVID-19 may have already peaked last year, the global market for psychedelic drugs is still in the early stages of a steep growth curve. Between 2022 and 2029, market research firm Data Bridge Market Research projects a compound annual growth rate of 13%. That would equate to an increase in market volume from the current USD 2.39 billion to USD 6.40 billion by then.

    There are approximately 350 million people living with depression in the world. According to estimates by the World Health Organization (WHO), only one in four sufferers receives adequate treatment. This makes depression the most important cause of illness of all. Apart from prescribing antidepressants, which usually have severe side effects, there are currently few alternative treatment methods. For some years now, however, the "mental health" sector has been revolutionized, primarily by innovative biotech companies.

    In addition to the top dog Compass Pathways, which reigns supreme with a market capitalization of USD 415.87 million, more and more smaller development companies such as XPhyto or Core One Labs are conducting research in this segment. Vancouver-based Core One Labs, which currently has a market cap of CAD 34.18 million, is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, advancing assisted treatments, and integrating new drug delivery technologies. In doing so, the Canadians are taking a multi-faceted business approach, integrating multiple complementary business units and entities to establish themselves as an industry leader in the rapidly growing and emerging psychedelics market.

    Core One Labs seeks big brother

    For example, Core One Labs, through its wholly-owned subsidiary Vocan Biotechnologies Inc. developed a patent-pending proprietary psilocybin production system using modified bacteria. In addition, the Company holds four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental disorders under its wholly owned subsidiary Akome Biotech Ltd. and three provisional patents under its other wholly owned subsidiary, Awaken BioSciences Inc. for additional synthetic technologies for psilocybin and psilocin production methods.

    It has now been announced that the current path will not be continued alone. Core One is actively seeking investment and potential acquisition opportunities by strategic psychedelics or pharmaceutical companies. Once a suitable offer is received and an agreement is reached, the Company will inform shareholders and the market and provide all necessary details of the transaction. According to management, an acquisition could represent a unique opportunity for Core One and its shareholders to enter new markets and product lines, and for Core One to benefit from the strengths and synergies of a buyer. This, in turn, could increase Core One's market share and strengthen its competitive advantage in the lucrative and fast-growing psychedelics industry. From a technical perspective, the chart formed a saucer formation in recent months. A breakout above the CAD 1.21 level would open up a price potential of around 88% to CAD 2.32.

    XPhyto - Broad-based accelerator

    Unlike Core One, German-Canadian company XPhyto is not actively seeking buyers for its highly scalable platform technology. However, assuming further research successes, interest from major players in the biotech or pharma industries could steadily increase. In all three business areas, significant successes have been recorded in recent weeks.

    For example, the diversified bioscience accelerator, which focuses on next-generation drug formulations, diagnostics, and new active pharmaceutical ingredients, submitted a patent application for its substantial collection of novel psychedelic compounds. Here, the compound database can be targeted for the treatment of neuropsychiatric, neurodegenerative and neuroinflammatory disorders, including depression, tobacco, opiate and cocaine addiction, or alcoholism, among others.

    In addition, XPhyto reported positive in vivo results of a Rotigotine transdermal patch for the treatment of Parkinson's disease. Rotigotine is an active ingredient already approved in Europe and the US for the treatment of Parkinson's disease and restless legs syndrome (RLS). Here, XPhyto compared an active ingredient patch currently on the market with the patch developed by its German subsidiary Vektor Pharma TF GmbH. The results for the criteria "penetration of the skin" as well as "dissolution behavior of the active ingredient" clearly exceeded the predictions. Thus, nothing should stand in the way of transferring the developed Rotigotine patch to an in vivo study. If the study progresses positively, it should then be another 6 to 12 months before market launch. A detailed background is available at researchanalyst.com.

    In the third sector, the Diagnostics Division, a binding letter of intent was also signed with a US company to cooperate in the field of thin-film screening tests. The partnership is to revolve around manufacturing, distribution, research and development with the group, which has production capacities that meet the requirements of the US Food and Drug Administration.

    From a chart perspective, XPhyto's stock has also been able to form a saucer formation in recent months, trading at CAD 0.49 on the Toronto Stock Exchange. A break of resistance at CAD 0.56 would also open up significant upside potential to the CAD 0.70 area.


    The biotech sector corrected strongly in recent weeks, and the growth potential, especially in second-tier stocks, is enormous. While Core One Labs is actively looking for a buyer, XPhyto is rushing from success to success in its three business areas.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read